{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:21Z","timestamp":1792154001740,"version":"4.4.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n            There is an urgent need for new, potent antituberculosis (anti-TB) drugs with novel mechanisms of action that can be included in new regimens to shorten the treatment period for TB. After screening a library of carbostyrils, we optimized 3,4-dihydrocarbostyril derivatives and identified OPC-167832 as having potent antituberculosis activity. The MICs of the compound for\n            <jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>\n            ranged from 0.00024 to 0.002\u2009\u03bcg\/ml. It had bactericidal activity against both growing and intracellular bacilli, and the frequency of spontaneous resistance for\n            <jats:named-content content-type=\"genus-species\">M. tuberculosis<\/jats:named-content>\n            H37Rv was less than 1.\n          <\/jats:p>","DOI":"10.1128\/aac.02020-19","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T13:05:03Z","timestamp":1585227903000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":135,"title":["OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor"],"prefix":"10.1128","volume":"64","author":[{"given":"Norimitsu","family":"Hariguchi","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhao","family":"Chen","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kawano","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Matsuba","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ohba","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuru","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Kitamoto","sequence":"additional","affiliation":[{"name":"Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunpei","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Itotani","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Takemura","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Global tuberculosis report 2018. Document WHO\/CDS\/TB\/2018.20. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00151-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31882-3"},{"key":"e_1_3_3_5_2","volume-title":"Target Regimen Profiles for TB Treatment","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Target Regimen Profiles for TB Treatment. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/tb\/publications\/TRP_profiles\/en\/."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.06.027"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-013-5218-x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S37743"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582325"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01903-13"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02583-13"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2017.12.006"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2008.08.003"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.187.23.8020-8025.2005"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2008.06395.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303575"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986710791959693"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0125"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171583"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309171110"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03233-14"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004395"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm5002937"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw502"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1039\/C8RA00720A"},{"key":"e_1_3_3_26_2","volume-title":"WHO treatment guidelines for rifampin- and multidrug-resistant tuberculosis, 2018 update","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. WHO treatment guidelines for rifampin- and multidrug-resistant tuberculosis, 2018 update. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/tb\/areas-of-work\/drug-resistant-tb\/guideline-update2018\/en\/."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0611OC"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv183"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2007.12.002"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02041-15"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00217-12"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.019570"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00127"},{"key":"e_1_3_3_34_2","unstructured":"Otsuka Pharmaceutical Development and Commercialization Inc. 2018. A Phase 1\/2 trial of multiple oral doses of OPC-167832 for uncomplicated pulmonary tuberculosis. ClinicalTrials.gov identifier NCT03678688. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03678688."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05293-11"},{"key":"e_1_3_3_36_2","volume-title":"Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00149.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.6.2996-2997.2005"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205735109"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00778-15"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1466"},{"key":"e_1_3_3_43_2","unstructured":"Science Council of Japan. 2006. Guidelines for proper conduct of animal experiments. Science Council of Japan. http:\/\/www.scj.go.jp\/en\/animal\/."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890260207"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01691-15"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1341"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02020-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02020-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:47:25Z","timestamp":1645480045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02020-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.02020-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02020-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2019-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02020-19"}}